Join        Login             Stock Quote

Oculus Innovative Sciences (OCLS) To Create Subsidiary For Anti-Infective Drug Assets

 November 26, 2012 11:42 AM

(By Balaseshan) Oculus Innovative Sciences Inc. (NASDAQ: OCLS) said it has initiated the process to create a wholly owned subsidiary that will hold the commercial healthcare company's anti-infective drug assets.

The company recently announced, that based upon market research, there appeared to be a significant opportunity for a new drug utilizing the Microcyn Technology for surgical suite use.

The company's new surgical formulation has been finalized and the company is now preparing the clinical strategy in preparation for discussions with the FDA.

Oculus management believes that the creation of this subsidiary will provide focused resources for the drug development platform as well as financing opportunities specific to the subsidiary, or future spinoff.

[Related -Watch This Alternative Investment for a Buy Signal]

The objective is to generate funding for the company's FDA clinical trials without issuing additional shares of the parent company.

"The creation of a subsidiary allows us to better leverage our drug opportunities, including Oculus' surgical anti-infective program. We plan on exploring all strategic alternatives to unlock the value of these assets, which we believe will lead to new drug applications for Microcyn Technology within the surgical suite," said Hoji Alimi, founder and CEO of Oculus.

The company said the new subsidiary could allow its existing shareholders to gain equity in both entities, and moving forward should attract both biotech investors focused on its drug programs as well as fundamental investors whose priority is the sales growth and profitability of its medical device products.

[Related -US REITs Edged Higher Last Week As Emerging Markets Slumped]

OCLS is trading up 1.43% at $0.710 on Monday. The stock has been trading between $0.60 and $1.65 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageWatch This Alternative Investment for a Buy Signal

All major U.S. indices closed essentially unchanged last week except for the small-cap Russell 2000. While read on...

article imageUS REITs Edged Higher Last Week As Emerging Markets Slumped

Real estate investment trusts (REITs) in the US took the lead in last week’s shortened holiday trading week read on...

article imageA Contrarian Perspective On The Short EuroTtrade

As the euro continues to drift lower, it has become the accepted wisdom that we are headed for parity with read on...

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.